debate: targeted therapy for ras/braf wt left sided colon cancers - bevacizumab or egfr antibodies
Published 7 years ago • 4.7K plays • Length 11:54Download video MP4
Download video MP3
Similar videos
-
17:17
debate: targeted therapy for ras/braf wt left sided colon cancers - egfr antibodies are mandatory
-
8:20
debate: first line egfr therapy for left sided ras/braf wt metastatic colon cancer? - yes
-
16:56
colorectal cancer with acquired resistance to egfr antibodies: how to manage?
-
7:37
debate: msi high colon cancer - upfront chemotherapy
-
10:30
debate 1: first-line treatment of metastatic colorectal cancer - fire-3
-
15:52
debate: are novel targets such as her2 ready for prime time in colorectal cancer? - no
-
11:15
debate: borderline resectable liver metastasis in ras wt crc? - folfox (or folfoxiri)/bev
-
6:06
colorectal cancer debate: first line braf v600e - targeted triplet
-
1:12
targeted therapies in metastatic colorectal cancer
-
20:52
what is the optimal therapy for braf mutant metastatic colorectal cancer?
-
22:50
update: left versus right sided colon cancers: biomarkers versus biology
-
7:42
egfr-targeted therapy in metastatic colorectal cancer
-
8:44
debate: optimal salvage therapy for refractory colon cancer? - tas102 or regorafenib
-
1:21
what is the difference between targeted therapy, precision therapy, and immunotherapy?
-
13:46
choosing between anti-vegf and anti-egfr targeted therapy
-
1:22
braf mutations and mek inhibitors
-
9:12
debate: is there an optimal treatment for refractory colorectal cancer? - immunotherapy